ReviewTissue antigens2002
The CD1 family and T cell recognition of lipid antigens.
Review in Tissue antigens, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 68 citations in OpenAlex.
- Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.Theranostics · 2025Review
- Single-cell mRNA analysis and surface marker expression profiling of circulating immune cells in humans with alpha-gal syndrome.Frontiers in immunology · 2025Article
- The elusive case of human intraepithelial T cells in gut homeostasis and inflammation.Nature reviews. Gastroenterology & hepatology · 2018Review
- It Takes "Guts" to Cause Joint Inflammation: Role of Innate-Like T Cells.Frontiers in immunology · 2018Review
- Article
- KillingMicrobiology spectrum · 2017Review
- Leishmania infantum amastigotes trigger a subpopulation of human B cells with an immunoregulatory phenotype.PLoS neglected tropical diseases · 2015Article
- Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy.Cancers · 2011Article
- Evasion and subversion of antigen presentation by Mycobacterium tuberculosis.Tissue antigens · 2009Review
- TLR-independent induction of human monocyte IL-1 by phosphoglycolipids from thermophilic bacteria.Glycoconjugate journal · 2008Article
- Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule.The Journal of experimental medicine · 2005Article
- Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.The American journal of pathology · 2004Article
- Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders.Springer seminars in immunopathology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
For many years it was thought that T lymphocytes recognized only peptide antigens presented by MHC class I or class II molecules. Recently, it has become clear that a wide variety of lipids and glycolipids are also targets of the T cell response. This novel form of cell-mediated immune recognition is mediated by a family of lipid binding and presenting molecules known as CD1. The CD1 proteins represent a small to moderate sized family of beta2-microglobulin-associated transmembrane proteins that are distantly related to MHC class I and class II molecules. They are conserved in most or all mammals, and control the development and function of T cell populations that participate in innate and adaptive immune responses through the recognition of self and foreign lipid antigens. Here we review the current state of our understanding of the structure and function of CD1 proteins, and the role of CD1-restricted T cell responses in the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.